Bristol’s Mavacamten Shows Consistent Efficacy, Safe Use In Obstructive HCM At ACC
US FDA Decision On First Indication Due On 28 April
Long-term results from the EXPLORER-HCM extension study are consistent with the pivotal trial in obstructive hypertrophic cardiomyopathy, while data from VALOR may support a supplemental filing.
